ENTX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.720

Open

1.720

VWAP

1.66

Vol

226.09K

Mkt Cap

81.82M

Low

1.610

Amount

376.06K

EV/EBITDA(TTM)

--

Total Shares

49.29M

EV

80.15M

EV/OCF(TTM)

--

P/S(TTM)

--

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Show More

Events Timeline

(ET)

2026-06-22

10:00:00

Entera Bio Receives FDA Feedback on EB613

2026-05-08 (ET)

2026-05-08

16:30:00

Entera Bio Files to Sell 19.57M Ordinary Shares

2026-03-04 (ET)

2026-03-04

08:40:00

Entera Bio Submits Clinical Amendment for EB613

2026-02-09 (ET)

2026-02-09

09:00:00

Entera Bio Appoints Geno Germano as Chairman of the Board

2026-02-04 (ET)

2026-02-04

08:20:00

OPKO Health Expands Collaboration Agreement with Entera Bio

2026-01-21 (ET)

2026-01-21

08:40:00

Entera Bio Expects Corporate Milestones in Q1 2026

2025-12-23 (ET)

2025-12-23

08:50:00

Entera Bio Welcomes FDA Qualification of Bone Density as Regulatory Endpoint for New Drugs

News

Newsfilter

06-23Newsfilter

Entera Bio Receives Positive FDA Feedback for EB613 Phase 3 Trial Approval

stocktwits

06-22stocktwits

Entera Bio's Bone Density Treatment Trial Progress

Newsfilter

06-22Newsfilter

Entera Bio Initiates Phase 3 Trial for EB613 in Osteoporosis

Newsfilter

06-16Newsfilter

Entera Bio Reports Preclinical Data for EB612 and EB618

Newsfilter

04-20Newsfilter

Entera Bio Hosts KOL Roundtable on EB613 for Osteoporosis

Newsfilter

04-06Newsfilter

Entera Bio Secures $10 Million in Private Placement Financing

1 Analyst Rating

Wall Street analysts forecast ENTX stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

10.00

Averages

10.00

High

10.00

Current: 0.000

Low

10.00

Averages

10.00

High

10.00

H.C. Wainwright

Buy

to

Buy

downgrade

$10 -> $9

AI Analysis

2026-04-27

Reason

H.C. Wainwright

Price Target

$10 -> $9

AI Analysis

2026-04-27

downgrade

Buy

to

Buy

Reason

H.C. Wainwright lowered the firm's price target on Entera Bio to $9 from $10 and keeps a Buy rating on the shares.

Valuation Metrics

The current forward P/E ratio for Entera Bio Ltd (ENTX.O) is 0.00, compared to its 5-year average forward P/E of -4.14. For a more detailed relative valuation and DCF analysis to assess Entera Bio Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.14

Current PE

0.00

Overvalued PE

-1.89

Undervalued PE

-6.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1237.33

Current PS

0.00

Overvalued PS

3708.56

Undervalued PS

-1233.91

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

give me a very bullish stock for today

Intellectia · 94 candidates

Price: >= $-100.00Rsi Category: moderatePrice Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceAboveMA200Ema 5: >= -100Ema 20: >= -100Ema 60: >= -100Macd: positive, bullish

Ticker

Name

Market Cap$

Entera Bio Ltd

72.95M

Getty Images Holdings Inc

481.80M

Elite Express Holding Inc

11.92M

Eshallgo Inc

8.21M

GP-Act III Acquisition Corp

391.72M

GigaMedia Ltd

16.14M

please list me the top moving penny stocks

Intellectia · 65 candidates

Price: $0.10 - $5.00Volume: >= 0Price Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 0

Ticker

Name

Market Cap$

Eshallgo Inc

8.21M

Getty Images Holdings Inc

481.80M

Tenon Medical Inc

7.19M

Sky Quarry Inc

9.11M

CDT Equity Inc

7.29M

Azitra Inc

3.72M

best option put tickers for rest of day

Intellectia · 1032 candidates

Volume: >= 200,000Price Change Pct: <= $-1.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceBelowMA20Is Optionable: True

Ticker

Name

Market Cap$

Cambium Networks Corp

49.99M

Taskus Inc

949.08M

Journey Medical Corp

227.14M

Cibus Inc

198.59M

MillerKnoll Inc

1.32B

Dyadic International Inc

31.57M

what stocks tomorrow are gonna be volatile

Intellectia · 11 candidates

Price Change Pct: >= $5.00Beta: HighRiskOption Iv Rank: >= 40

Ticker

Name

Market Cap$

Generac Holdings Inc

12.61B

Entera Bio Ltd

75.21M

Karyopharm Therapeutics Inc

134.95M

Outlook Therapeutics Inc

34.51M

Carparts.Com Inc

41.60M

AXT Inc

1.48B

Whales Holding ENTX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Entera Bio Ltd (ENTX) stock price today?

The current price of ENTX is 1.66 USD — it has decreased -2.92

What is Entera Bio Ltd (ENTX)'s business?

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

What is the price predicton of ENTX Stock?

Wall Street analysts forecast ENTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTX is10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Entera Bio Ltd (ENTX)'s revenue for the last quarter?

Entera Bio Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Entera Bio Ltd (ENTX)'s earnings per share (EPS) for the last quarter?

Entera Bio Ltd. EPS for the last quarter amounts to -0.07 USD, increased 16.67

How many employees does Entera Bio Ltd (ENTX). have?

Entera Bio Ltd (ENTX) has 20 emplpoyees as of July 08 2026.

What is Entera Bio Ltd (ENTX) market cap?

Today ENTX has the market capitalization of 81.82M USD.